Transcatheter arterial chemoembolization plus apatinib with or without camrelizumab for unresectable hepatocellular carcinoma: a multicenter retrospective cohort study

BACKGROUND: The evidence of transcatheter arterial chemoembolization (TACE) plus tyrosine kinase inhibitor and immune checkpoint inhibitor in unresectable hepatocellular carcinoma (HCC) was limited. This study aimed to evaluate the role of TACE plus apatinib (TACE + A) and TACE combined with apatini...

Descripción completa

Detalles Bibliográficos
Autores principales: Duan, Xuhua, Li, Hao, Kuang, Donglin, Chen, Pengfei, Zhang, Kai, Li, Yanliang, He, Xiang, Xing, Cheng, Wang, Haibo, Liu, Yaoxian, Xie, Limin, Zhang, Shixi, Zhang, Qiang, Zhu, Peixin, Dong, Honglin, Xie, Jichen, Li, Hui, Wang, Yong, Shi, Ming, Jiang, Guangbin, Xu, Yandong, Zhou, Shiqi, Shang, Chunyu, Ren, Jianzhuang, Han, Xinwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer India 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10386927/
https://www.ncbi.nlm.nih.gov/pubmed/37012542
http://dx.doi.org/10.1007/s12072-023-10519-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10386927/
https://www.ncbi.nlm.nih.gov/pubmed/37012542
http://dx.doi.org/10.1007/s12072-023-10519-8

Ejemplares similares